A citation-based method for searching scientific literature

Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older.
George G Nomikos, Dapo Tomori, Wei Zhong, John Affinito, William Palo. CNS Spectr 2017
Times Cited: 6






Login to export Results
Don't have an account? Register here

List of co-cited articles
48 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder.
Enric Alvarez, Victor Perez, Marianne Dragheim, Henrik Loft, Francesc Artigas. Int J Neuropsychopharmacol 2012
130
4
66

Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.
Benny Bang-Andersen, Thomas Ruhland, Morten Jørgensen, Garrick Smith, Kristen Frederiksen, Klaus Gjervig Jensen, Huailing Zhong, Søren Møller Nielsen, Sandra Hogg, Arne Mørk,[...]. J Med Chem 2011
221
4
66

A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder.
Cornelius Katona, Thomas Hansen, Christina Kurre Olsen. Int Clin Psychopharmacol 2012
215
4
66

A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD).
David S Baldwin, Henrik Loft, Marianne Dragheim. Eur Neuropsychopharmacol 2012
93
3
50

A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder.
Neven Henigsberg, Atul R Mahableshwarkar, Paula Jacobsen, Yinzhong Chen, Michael E Thase. J Clin Psychiatry 2012
89
3
50

Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder.
Jean-Philippe Boulenger, Henrik Loft, Christina Kurre Olsen. Int Clin Psychopharmacol 2014
94
3
50

Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
Mohammed Y Alam, Paula L Jacobsen, Yinzhong Chen, Michael Serenko, Atul R Mahableshwarkar. Int Clin Psychopharmacol 2014
41
3
50

Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data.
Connie Sanchez, Karen E Asin, Francesc Artigas. Pharmacol Ther 2015
186
3
50

A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms.
David S Baldwin, Ioana Florea, Paula L Jacobsen, Wei Zhong, George G Nomikos. J Affect Disord 2016
22
3
50

The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.
David S Baldwin, Lambros Chrones, Ioana Florea, Rebecca Nielsen, George G Nomikos, William Palo, Elin Reines. J Psychopharmacol 2016
43
3
50

Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.
Andrea Cipriani, Toshi A Furukawa, Georgia Salanti, Anna Chaimani, Lauren Z Atkinson, Yusuke Ogawa, Stefan Leucht, Henricus G Ruhe, Erick H Turner, Julian P T Higgins,[...]. Lancet 2018
630
3
50

Occupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjects.
Johan Areberg, Michael Luntang-Jensen, Birgitte Søgaard, Dorrit Ø Nilausen. Basic Clin Pharmacol Toxicol 2012
38
2
33

Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant.
Grace Chen, Ronald Lee, Astrid-Maria Højer, Jeppe Klint Buchbjerg, Michael Serenko, Zhen Zhao. Clin Drug Investig 2013
42
2
33

A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
Rakesh Jain, Atul R Mahableshwarkar, Paula L Jacobsen, Yinzhong Chen, Michael E Thase. Int J Neuropsychopharmacol 2013
74
2
33

Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004.
Mette G Hvenegaard, Benny Bang-Andersen, Henrik Pedersen, Morten Jørgensen, Ask Püschl, Lars Dalgaard. Drug Metab Dispos 2012
41
2
33

Biosynthesis and identification of an N-oxide/N-glucuronide metabolite and first synthesis of an N-O-glucuronide metabolite of Lu AA21004.
Henriette Kold Uldam, Martin Juhl, Henrik Pedersen, Lars Dalgaard. Drug Metab Dispos 2011
20
2
33

Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder.
Mélanie Brignone, Françoise Diamand, Caroline Painchault, Shweta Takyar. Curr Med Res Opin 2016
14
2
33

Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction.
Alan L Pehrson, Connie Sanchez. CNS Spectr 2014
88
2
33

The clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young volunteers.
Johan Areberg, Birgitte Søgaard, Astrid-Maria Højer. Basic Clin Pharmacol Toxicol 2012
39
2
33

Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.
Jeffrey H Meyer, Alan A Wilson, Sandra Sagrati, Doug Hussey, Anna Carella, William Z Potter, Nathalie Ginovart, Edgar P Spencer, Andy Cheok, Sylvain Houle. Am J Psychiatry 2004
301
2
33

Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters--a rat microdialysis and electrophysiology study.
Alan L Pehrson, Thomas Cremers, Cecile Bétry, Marieke G C van der Hart, Laerke Jørgensen, Mathias Madsen, Nasser Haddjeri, Bjarke Ebert, Connie Sanchez. Eur Neuropsychopharmacol 2013
91
2
33

Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats.
Arne Mørk, Liliana P Montezinho, Silke Miller, Crista Trippodi-Murphy, Niels Plath, Yan Li, Maria Gulinello, Connie Sanchez. Pharmacol Biochem Behav 2013
85
2
33

5-HTT and 5-HT(1A) receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects.
Per Stenkrona, Christer Halldin, Johan Lundberg. Eur Neuropsychopharmacol 2013
38
2
33

Vortioxetine: a New Treatment for Major Depressive Disorder.
K Ryan Connolly, Michael E Thase. Expert Opin Pharmacother 2016
23
2
33

Cognitive impairment in the remitted state of unipolar depressive disorder: a systematic review.
Bo Jacob Hasselbalch, Ulla Knorr, Lars Vedel Kessing. J Affect Disord 2011
211
2
33

A new depression scale designed to be sensitive to change.
S A Montgomery, M Asberg. Br J Psychiatry 1979
7406
2
33

Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder.
Roger S McIntyre, Ioana Florea, Brigitte Tonnoir, Henrik Loft, Raymond W Lam, Michael Cronquist Christensen. J Clin Psychiatry 2017
33
2
33

Cognitive symptoms in patients with major depressive disorder and their implications for clinical practice.
George I Papakostas. J Clin Psychiatry 2014
74
2
33

Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder.
A Mørk, A Pehrson, L T Brennum, S Møller Nielsen, H Zhong, A B Lassen, S Miller, L Westrich, N J Boyle, C Sánchez,[...]. J Pharmacol Exp Ther 2012
167
2
33

A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults.
Roger S McIntyre, Søren Lophaven, Christina K Olsen. Int J Neuropsychopharmacol 2014
179
2
33

Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions.
Roger S McIntyre, Danielle S Cha, Joanna K Soczynska, Hanna O Woldeyohannes, Laura Ashley Gallaugher, Paul Kudlow, Mohammad Alsuwaidan, Anusha Baskaran. Depress Anxiety 2013
283
2
33

A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults.
Michael E Thase, Atul R Mahableshwarkar, Marianne Dragheim, Henrik Loft, Eduard Vieta. Eur Neuropsychopharmacol 2016
50
2
33

The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
Bernhard T Baune, Lasse B Sluth, Christina K Olsen. J Affect Disord 2018
18
2
33

Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders.
Michael Cronquist Christensen, Henrik Loft, Roger S McIntyre. J Affect Disord 2018
14
2
33

Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD).
Pratap Chokka, Joanna Bougie, Emmanouil Rampakakis, Jean Proulx. CNS Spectr 2019
12
2
33

Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder.
David S Baldwin, Thomas Hansen, Ioana Florea. Curr Med Res Opin 2012
41
2
33

A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD.
Atul R Mahableshwarkar, Paula L Jacobsen, Yinzhong Chen, Michael Serenko, Madhukar H Trivedi. Psychopharmacology (Berl) 2015
50
2
33

Vortioxetine: A new alternative for the treatment of major depressive disorder.
Estela Salagre, Iria Grande, Brisa Solé, Jose Sanchez-Moreno, Eduard Vieta. Rev Psiquiatr Salud Ment 2018
9
2
33

Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response.
George I Papakostas, Rebecca Z Nielsen, Marianne Dragheim, Brigitte Tonnoir. J Psychiatr Res 2018
4
2
50

A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
Atul R Mahableshwarkar, Paula L Jacobsen, Yinzhong Chen. Curr Med Res Opin 2013
71
2
33

Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction.
Paula L Jacobsen, Atul R Mahableshwarkar, Yinzhong Chen, Lambros Chrones, Anita H Clayton. J Sex Med 2015
32
2
33

Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder.
Michael E Thase, Natalya Danchenko, Melanie Brignone, Ioana Florea, Francoise Diamand, Paula L Jacobsen, Eduard Vieta. Eur Neuropsychopharmacol 2017
10
2
33

Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study.
Paula L Jacobsen, Linda Harper, Lambros Chrones, Serena Chan, Atul R Mahableshwarkar. Int Clin Psychopharmacol 2015
16
2
33

Treatment of cognitive dysfunction in major depressive disorder--a review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine.
Alan L Pehrson, Steven C Leiser, Maria Gulinello, Elena Dale, Yan Li, Jessica A Waller, Connie Sanchez. Eur J Pharmacol 2015
45
2
33

New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder.
Cornelius L Katona, Cara P Katona. Neuropsychiatr Dis Treat 2014
25
2
33

The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram.
Eduard Vieta, Lasse B Sluth, Christina K Olsen. J Affect Disord 2018
14
2
33

[Vortioxetine in the treatment of major depression].
Andrea de Bartolomeis, Andrea Fagiolini, Giuseppe Maina. Riv Psichiatr 2016
4
2
50

A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder.
Paula L Jacobsen, Atul R Mahableshwarkar, Michael Serenko, Serena Chan, Madhukar H Trivedi. J Clin Psychiatry 2015
56
2
33

The clinical relevance of plasma protein binding changes.
Jason A Roberts, Federico Pea, Jeffrey Lipman. Clin Pharmacokinet 2013
112
1
16

Effects of food on drug absorption.
P G Welling. Annu Rev Nutr 1996
100
1
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.

Longstocking, LLC. © 2020
Home | About Us | FAQs | Terms & Privacy